DrugPatentWatch Database Preview
XALKORI Drug Profile
When do Xalkori patents expire, and what generic alternatives are available?
Xalkori is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this compound. Additional details are available on the crizotinib profile page.
Summary for XALKORI
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 74 |
| Clinical Trials: | 27 |
| Patent Applications: | 133 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XALKORI |
| DailyMed Link: | XALKORI at DailyMed |
Generic Entry Opportunity Date for XALKORI
Generic Entry Date for XALKORI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for XALKORI
Synonyms for XALKORI
| (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine |
| (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine |
| (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine |
| (R)-crizotinib |
| 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)- |
| 2-PYRIDINAMINE, 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]- |
| 3-((1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1h-pyrazol-4-yl)pyridin-2-amine |
| 3-(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy-5-1-(4-piperidinyl)-1H-pyrazol-4-yl-2-Pyridinamine |
| 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine |
| 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[ |
| 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine |
| 3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE |
| 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine |
| 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine |
| 399P525 |
| 53AH36668S |
| 877399-52-5 |
| 877399-52-5, 877399-53-6 (acetate) |
| 912279-98-2 |
| AB0027203 |
| ABP000131 |
| AK172044 |
| AKOS015901233 |
| AKOS015995207 |
| AMX10152 |
| ANW-47749 |
| AOB2688 |
| BB 0261738 |
| BC622990 |
| BCPP000116 |
| BDBM50306682 |
| BRD-K78431006-001-01-1 |
| C21H22Cl2FN5O |
| CHEBI:64310 |
| CHEMBL601719 |
| Crizotinib |
| Crizotinib (JAN/USAN/INN) |
| Crizotinib (PF-02341066) |
| Crizotinib (PF-2341066) |
| Crizotinib [USAN:INN] |
| Crizotinib, >=98% (HPLC) |
| crizotinibum |
| CTK5F8952 |
| D03ZBT |
| D09731 |
| DB08865 |
| EN002685 |
| EX-A096 |
| FT-0665224 |
| GS-6178 |
| GTPL4903 |
| HY-50878 |
| I14-14837 |
| J-510370 |
| KB-26391 |
| KIN0000318 |
| KS-0000075X |
| KTEIFNKAUNYNJU-GFCCVEGCSA-N |
| MFCD12407409 |
| MolPort-009-679-404 |
| NCGC00250400-01 |
| novel ALK inhibitors |
| NSC-749005 |
| NSC749005 |
| PB11015 |
| PF 02341066 |
| PF 2341066 |
| PF 2341066;(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine |
| PF-02341066 |
| PF-02341066 (Crizotinib) |
| PF-2341066 |
| PF-2341066 - Crizotinib |
| PF-2341066 (Crizotinib) |
| PF-2341066,Crizotinib |
| PF-2341066(Crizotinib) |
| PF2341066 |
| PubChem19322 |
| Q-3209 |
| QCR-32 |
| RL05464 |
| SC-48062 |
| SCHEMBL93829 |
| SYN1139 |
| TX-017903 |
| UNII-53AH36668S |
| VGH |
| W9013 |
| Xalkori (TN) |
| ZINC35902489 |
US Patents and Regulatory Information for XALKORI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-001 | Aug 26, 2011 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-001 | Aug 26, 2011 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-001 | Aug 26, 2011 | RX | Yes | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for XALKORI
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 20070038562 | ➤ Try a Free Trial |
| Germany | 602006018354 | ➤ Try a Free Trial |
| South Africa | 200804777 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for XALKORI
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00587 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023 |
| 2013005 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023 |
| 0130007 00075 | Estonia | ➤ Try a Free Trial | PRODUCT NAME: KRISOTINIIB;REG NO/DATE: K(2012)7617 LOPLIK 23.10.2012 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
